PO-0957 Radiomics study from the dose-painting multicenter phase III trial on newly diagnosed glioblastoma
Fatima Tensaouti(Université Toulouse III - Paul Sabatier), Anne Laprie(Université Toulouse III - Paul Sabatier), T. Filleron, S. Ken(Institut Claudius Regaud), L. Vieillevigne, V. Lubrano(Université Toulouse III - Paul Sabatier), Franck Desmoulin(Université Toulouse III - Paul Sabatier), J. P. Bailleul, Patrice Péran(Université Toulouse III - Paul Sabatier), M. Charissoux(Institut de Recherche en Cancérologie de Montpellier), Julie Desrousseaux, Pierre Auberdiac, E. Cohen-Jonathan Moyal(Institut Claudius Regaud), I. Catalaa, Nicolas Magné, G. Noël(Hôpital Pierre Wertheimer), M. Sunyach, E. Martin(Institut de Cancérologie de l'Ouest), J.-A. Lotterie, G. Truc(Centre Georges François Leclerc)
Cited by 1
Related Papers
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
|Nature Communications|2020|121
Antigens of the basement membrane and the peritumoral stroma in human colonic adenocarcinomas: An immunofluorescence study
|International Journal of Cancer|1982|99
Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients
|Alcoholism Clinical and Experimental Research|1988|95